No Data
WUXI APPTEC: Q1 net profit significantly increased, maintaining double-digit growth guidance for the year | Interpretations
① WUXI APPTEC's Q1 net income attributable to the parent company grew 89.1% year-on-year, mainly due to revenue growth, improved overall profitability, and the sale of WUXI XDC stocks; ② WUXI APPTEC still believes it can achieve its annual double-digit growth target.
WUXI APPTEC: Q1 revenue of 9.655 billion yuan, a year-on-year growth of 21%, with strong performance in the Business driving significant growth.
WUXI APPTEC's first quarter of 2025: strong performance growth driven by the chemical Business, TIDES Business revenue surged by 187%. Key financial highlights...
Summit Therapeutics Shares Are Trading Lower. The Company's Partner Akeso Received FDA Approval for Its PD-1 Monoclonal Antibody, Penpulimab-kcqx, in Combination With Cisplatin or Carboplatin and Gemcitabine. The FDA Also Approved Penpulimab-kcqx as a...
'Akeso Wins Chinese Approval For Cancer Drug Positioned To Rival Merck's Keytruda; Company Discloses Early Data Hinting At A Survival Benefit' - STAT News
Summit Extends Gains as Cancer Drug Outperforms BeiGene's Tevimbra
Zai Lab To Present Data From Phase 1 Trial Of DLL3-Targeted Antibody-Drug Conjugate ZL-1310 At 2025 ASCO Annual Meeting